News

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment

Read More
Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA announces positive results from Phase 1/2 clinical trial in patients with severe bone non-union of the lower limb following trauma

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its

Read More
Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis

Ventyx Biosciences announces dosing of the first patient in the Phase 2 SERENITY trial of VTX958 for the treatment of moderate to severe plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for

Read More
Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Resolve Therapeutics completes enrollment of Phase II Long Covid clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, has announced that its Phase II clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121). The randomized, double-blind, placebo- controlled study in patients with long covid who are suffering from debilitating fatigue has enrolled

Read More
Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million

Novadip Biosciences raises additional EUR 40 Million bringing total company funding to EUR 88 Million

Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive

Read More
Phase Four unveils game changing engine for LEO Constellations

Phase Four unveils game changing engine for LEO Constellations

Leveraging its new Block 2 architecture, Phase Four announces Max-V, a revolutionary plasma propulsion system available in 2023. Phase Four, the creator of the radio-frequency thruster for satellite propulsion, has announced that it will expand its Maxwell turn-key plasma propulsion line and offer satellite manufacturers an industry-first high performance engine

Read More
Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958

Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958

Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a

Read More
Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space

Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space

Weaving together digital engineering and technology, Parker Aerospace today announced collaboration with Lockheed Martin and DUST Identity. The alliance implements DUST technology to connect Parker Aerospace products with Lockheed Martin aircraft to track parts from build to delivery and maintenance. The collaboration optimizes Parker Aerospace product traceability and supply chain

Read More
Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735

Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, has announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735,

Read More
Cambridge Epigenetix names Peter Fromen as Chief Executive Officer

Cambridge Epigenetix names Peter Fromen as Chief Executive Officer

Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022. Gail Marcus who has been acting Chief Executive Officer since 2020 will continue as Chair of the Board. Professor

Read More
Phase Four and Impulse Space to collaborate on multi-mode propulsion

Phase Four and Impulse Space to collaborate on multi-mode propulsion

Phase Four the creator of the radio-frequency thruster (RF Thruster) for satellite propulsion, has announced that it has signed a memorandum of understanding with Impulse Space, a Space 2.0 pioneer providing agile, economical last-mile space payload delivery capabilities. The companies seek to explore and collaborate on opportunities to develop and

Read More
Vascular Therapies completes $25 million private financing

Vascular Therapies completes $25 million private financing

Vascular Therapies, Inc. a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, has announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company. Vascular Therapies plans to use the proceeds

Read More